国家政策对手术和损伤患者阿片类药物处方的影响:北卡罗莱纳州控制中断时间序列研究,2014-2019。

IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Theo G Beltran, Brian W Pence, Naoko Fulcher, Nabarun Dasgupta, Courtney N Maierhofer, Bethany L DiPrete, Stephen W Marshall, Maryalice Nocera, Scott K Proescholdbell, Li-Tzy Wu, David A Edwards, Timothy S Carey, Paul R Chelminski, Juan M Hincapie-Castillo, Joacy G Mathias, Shabbar I Ranapurwala
{"title":"国家政策对手术和损伤患者阿片类药物处方的影响:北卡罗莱纳州控制中断时间序列研究,2014-2019。","authors":"Theo G Beltran, Brian W Pence, Naoko Fulcher, Nabarun Dasgupta, Courtney N Maierhofer, Bethany L DiPrete, Stephen W Marshall, Maryalice Nocera, Scott K Proescholdbell, Li-Tzy Wu, David A Edwards, Timothy S Carey, Paul R Chelminski, Juan M Hincapie-Castillo, Joacy G Mathias, Shabbar I Ranapurwala","doi":"10.1002/pds.70144","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Impact of policies limiting opioid prescribing for acute and post-surgical pain among racially minoritized populations is not well understood. We evaluated the impact of two North Carolina (NC) policies on outpatient opioid prescribing among injury and surgical patients by race, ethnicity, age, and sex.</p><p><strong>Methods: </strong>We conducted controlled and single series interrupted time series using electronic health data from two integrated healthcare systems in NC, among > 11 years-old patients having acute injuries and surgery between April 2014 and December 2019. The policy interventions were safe opioid prescribing investigative initiative (SOPI, May 2016) and NC law limiting opioid days' supply (STOP Act, January 2018). Outcomes included, proportion of patients receiving index opioid prescription after surgery or injury event, receipt of subsequent opioid prescriptions, days' supply, and milligrams of morphine equivalents (MME).</p><p><strong>Results: </strong>Of the 621 997 surgical and 864 061 injury patients, 69.4% and 19.7%, respectively, received an index opioid analgesic prescription. There were sustained declines in index opioid prescription among post-surgical patients after SOPI [-2.7% per year (-4.6, -0.9)] and STOP act [-4.1% (-5.9, -2.2)], but no change among injury patients. Policy-related opioid prescribing declines were larger among black, native American, and Hispanic post-surgical patients than whites and Asians. Index and subsequent opioid days' supply showed sustained declines after SOPI and STOP Act among post-surgical patients. There was no policy impact on MME.</p><p><strong>Conclusions: </strong>Policies were associated with reductions in opioid prescribing, particularly in post-surgical patients; however, racialized inequities likely reflect implicit and explicit racialized biases in pain management practices.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 4","pages":"e70144"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082966/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of State Policies on Opioid Prescribing Among Surgery and Injury Patients: Controlled Interrupted Time-Series Study, North Carolina, 2014-2019.\",\"authors\":\"Theo G Beltran, Brian W Pence, Naoko Fulcher, Nabarun Dasgupta, Courtney N Maierhofer, Bethany L DiPrete, Stephen W Marshall, Maryalice Nocera, Scott K Proescholdbell, Li-Tzy Wu, David A Edwards, Timothy S Carey, Paul R Chelminski, Juan M Hincapie-Castillo, Joacy G Mathias, Shabbar I Ranapurwala\",\"doi\":\"10.1002/pds.70144\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Impact of policies limiting opioid prescribing for acute and post-surgical pain among racially minoritized populations is not well understood. We evaluated the impact of two North Carolina (NC) policies on outpatient opioid prescribing among injury and surgical patients by race, ethnicity, age, and sex.</p><p><strong>Methods: </strong>We conducted controlled and single series interrupted time series using electronic health data from two integrated healthcare systems in NC, among > 11 years-old patients having acute injuries and surgery between April 2014 and December 2019. The policy interventions were safe opioid prescribing investigative initiative (SOPI, May 2016) and NC law limiting opioid days' supply (STOP Act, January 2018). Outcomes included, proportion of patients receiving index opioid prescription after surgery or injury event, receipt of subsequent opioid prescriptions, days' supply, and milligrams of morphine equivalents (MME).</p><p><strong>Results: </strong>Of the 621 997 surgical and 864 061 injury patients, 69.4% and 19.7%, respectively, received an index opioid analgesic prescription. There were sustained declines in index opioid prescription among post-surgical patients after SOPI [-2.7% per year (-4.6, -0.9)] and STOP act [-4.1% (-5.9, -2.2)], but no change among injury patients. Policy-related opioid prescribing declines were larger among black, native American, and Hispanic post-surgical patients than whites and Asians. Index and subsequent opioid days' supply showed sustained declines after SOPI and STOP Act among post-surgical patients. There was no policy impact on MME.</p><p><strong>Conclusions: </strong>Policies were associated with reductions in opioid prescribing, particularly in post-surgical patients; however, racialized inequities likely reflect implicit and explicit racialized biases in pain management practices.</p>\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"34 4\",\"pages\":\"e70144\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082966/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.70144\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70144","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:限制阿片类药物处方对少数种族人群急性和术后疼痛的影响尚不清楚。我们根据种族、民族、年龄和性别评估了北卡罗来纳州(NC)两项政策对受伤和手术患者门诊阿片类药物处方的影响。方法:利用北卡罗来纳州两个综合医疗保健系统的电子健康数据,对2014年4月至2019年12月期间发生急性损伤和手术的bb1011岁患者进行对照和单序列中断时间序列研究。政策干预措施是安全阿片类药物处方调查倡议(SOPI, 2016年5月)和限制阿片类药物日供应的北卡罗来纳州法律(STOP Act, 2018年1月)。结果包括手术或损伤事件后接受阿片类药物指数处方的患者比例,随后阿片类药物处方的收据,天数供应和吗啡当量毫克数(MME)。结果:621 997例手术患者和864 061例外伤患者中,分别有69.4%和19.7%的患者使用了指数阿片类镇痛药处方。SOPI术后患者阿片类药物处方指数持续下降[-2.7% /年(-4.6,-0.9)]和STOP act[-4.1%(-5.9, -2.2)],但损伤患者无变化。与政策相关的阿片类药物处方在黑人、美洲原住民和西班牙裔术后患者中的下降幅度大于白人和亚洲人。术后患者在SOPI和STOP法案后,阿片类药物日供应指数和随后的阿片类药物日供应持续下降。结论:政策与阿片类药物处方的减少有关,特别是在术后患者中;然而,种族化的不平等可能反映了疼痛管理实践中的隐性和显性种族化偏见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of State Policies on Opioid Prescribing Among Surgery and Injury Patients: Controlled Interrupted Time-Series Study, North Carolina, 2014-2019.

Purpose: Impact of policies limiting opioid prescribing for acute and post-surgical pain among racially minoritized populations is not well understood. We evaluated the impact of two North Carolina (NC) policies on outpatient opioid prescribing among injury and surgical patients by race, ethnicity, age, and sex.

Methods: We conducted controlled and single series interrupted time series using electronic health data from two integrated healthcare systems in NC, among > 11 years-old patients having acute injuries and surgery between April 2014 and December 2019. The policy interventions were safe opioid prescribing investigative initiative (SOPI, May 2016) and NC law limiting opioid days' supply (STOP Act, January 2018). Outcomes included, proportion of patients receiving index opioid prescription after surgery or injury event, receipt of subsequent opioid prescriptions, days' supply, and milligrams of morphine equivalents (MME).

Results: Of the 621 997 surgical and 864 061 injury patients, 69.4% and 19.7%, respectively, received an index opioid analgesic prescription. There were sustained declines in index opioid prescription among post-surgical patients after SOPI [-2.7% per year (-4.6, -0.9)] and STOP act [-4.1% (-5.9, -2.2)], but no change among injury patients. Policy-related opioid prescribing declines were larger among black, native American, and Hispanic post-surgical patients than whites and Asians. Index and subsequent opioid days' supply showed sustained declines after SOPI and STOP Act among post-surgical patients. There was no policy impact on MME.

Conclusions: Policies were associated with reductions in opioid prescribing, particularly in post-surgical patients; however, racialized inequities likely reflect implicit and explicit racialized biases in pain management practices.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.80
自引率
7.70%
发文量
173
审稿时长
3 months
期刊介绍: The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信